Navigation Links
Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
Date:4/9/2008

Phase III study will evaluate effects of otelixizumab, an investigational

anti-CD3 monoclonal antibody, on preservation of endogenous insulin

secretion

CAMBRIDGE, Mass., April 9, 2008 /PRNewswire/ - Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, today announced that it is proceeding toward the initiation of a Phase III study of otelixizumab in new-onset type 1 diabetes. Tolerx is initiating this pivotal trial after reviewing the results of the otelixizumab development program with the US Food and Drug Administration (FDA) at an End of Phase II meeting.

The Phase III study, known as DEFEND (Durable Response Therapy Evaluation For Early or New Onset Type 1 Diabetes), will be conducted at multiple centers in North America and Europe and will evaluate whether a single course of otelixizumab reduces the amount of administered insulin required for control of blood glucose levels by inhibiting destruction of beta cells. Maintenance of beta cell function has been associated with improved glycemic control (HbA1c levels), fewer hypoglycemic events and reduction of long term disease complications in established diabetics in the Diabetes Control and Complications Trial (DCCT). DEFEND enrollment is expected to begin mid-2008.

"We are very pleased with the outcome of the End of Phase II meeting with FDA and the opportunity to advance initiation of the DEFEND trial. This step is a significant and important milestone for Tolerx," said Dr. Douglas J. Ringler, President and Chief Executive Officer of Tolerx. "The rigorous science behind our Phase II clinical program has provided us with valuable insights that facilitated our moving forward into DEFEND with an optimized dosing regimen that has the potential to transform the treatment paradigm for type 1 diabetes."

"We have worked closely with FDA over several years to ensure that
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Novel Technology Breaks Through Cancer Pain
3. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
4. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
5. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
6. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
7. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
8. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
9. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
10. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
11. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- Today the US Surgeon General issued the most stern warning ... burns stating they can lead directly to deadly melanoma skin ... says that "skin cancer is a major public health problem ... indoor and outdoor ultraviolet light is a major cause." At ... Boca Raton, Florida , Marta I. Rendon ...
(Date:7/30/2014)... , July 30, 2014 Research ... "Global and Chinese Aseptic Packaging Industry Report 2014" ... http://photos.prnewswire.com/prnh/20130307/600769 The Global and Chinese ... study on the current state of the global Aseptic ... The report provides a basic overview of the ...
(Date:7/30/2014)... 30, 2014  InnoPharma, Inc. today announced the first ... equivalent of Zyprexa® injection), in Canada.  Olanzapine is indicated ... in patients with schizophrenia or bipolar I mania. ... InnoPharma has entered into an agreement with Sandoz Canada ... make, use, sell, market and distribute Olanzapine Injection in ...
Breaking Medicine Technology:Indoor and Outdoor Sun Tanning or Sun Burns Directly Linked to Deadly Melanoma Skin Cancer 2Global and Chinese Aseptic Packaging Industry Report 2014 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2
... Life Technologies Corporation (NASDAQ: ... an agreement with GlaxoSmithKline Biologicals S.A. (GSK) to develop ... with a GSK candidate cancer immunotherapy. Specifically, Life will ... cancer immunotherapy candidate designed to identify patients likely to ...
... Desert Radiologists has earned Breast MRI accreditation from ... first facility in Las Vegas to receive this prestigious ... that the breast MRI at Desert Radiologists meets ACR,s ... quality control procedures and quality assurance programs. ...
Cached Medicine Technology:Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics 2Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics 3Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics 4Desert Radiologists Earns ACR Breast MRI Accreditation 2
(Date:7/30/2014)... mutationslong known to fuel cancer as well as evolutionary ... rare events that occur randomly throughout the genome. , ... involves the formation of multiple mutations that arise simultaneously ... of clustered mutations are frequently found in regions where ... the journal Cell Reports , may one day ...
(Date:7/30/2014)... Hamilton Facial Plastic Surgery is ... office on July 30th. After months of planning, Dr. ... the state-of-the-art suite, located only steps away from the ... for one-on-one patient comfort, shorter wait times, and generally ... Hamilton’s new office-suite will continue to provide the same ...
(Date:7/30/2014)... NJ. July 30, 2014. A new network of 25 ... Stroke Trials Network (NIH StrokeNet) is working to ... U.S. Despite advances of the last two decades, ... stroke causes death or disability for 795,000 Americans. The ... of the population. , To accelerate the pace ...
(Date:7/30/2014)... 30, 2014 Over 630 doctors worldwide ... Technique®, the revolutionary minimally invasive treatment for gum recession. ... many of his peers to be the “father of ... a recent Chao Pinhole Surgical Technique® training course at ... is the recipient of the American Academy of Periodontics ...
(Date:7/30/2014)... Children’s Hospital of Michigan Foundation and Kohl’s invite ... to 7 p.m. Wednesday, August 6 at the Kohl’s ... 48152). The event will feature Detroit Red Wings defenseman ... and local public safety officials. Kohl’s will present a ... Foundation. , The gift supports Kohl’s Injury Prevention ...
Breaking Medicine News(10 mins):Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:Periodontist Dr. Dennis Shanelec Comments On The Chao Pinhole Surgical Technique® Training Course 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 3Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 4
... to a,recently published study, frequent mobile phone users ... study investigating the long term,effects of mobile phone ... that,frequent mobile phone users showed better focused attention, ... to making more phone calls in,distractive surroundings. No ...
... Hope, Jewelry Collection Donates 100% of Net Profits to The ... Ovarian Cancer ... commemorates,the 10th anniversary of its partnership with The Ovarian Cancer Research,Fund ... the past decade, L,Oreal Paris has offered hope to the tens ...
... 2007 -- WASHINGTON, DC) The Society for Cardiovascular ... Cardiology (ACC) announced today that they will hold a ... 2008. The meeting will be known as The SCAI ... It will be held concomitantly with the ACC Annual ...
... cases, patients never take these important medications again, study ... American seniors stop taking medications for chronic health problems ... exceed spending limits in their Medicare prescription drug plans, ... nonprofit research organization the RAND Corporation, also found that ...
... Va., Sept. 11 As part of an,initiative ... the cities visited,during its annual scientific meetings, the ... partnering with The Wellness Community -,South Bay Cities ... Volunteers from The Wellness Community will join forces ...
... , TUESDAY, Sept. 11 (HealthDay News) -- Short-term weight ... a new study shows. , Patients who gain as ... few weeks may require hospitalization within the month, according ... than 10 pounds are eight times more likely than ...
Cached Medicine News:Health News:'Slowed Brain-Activity' in Frequent Mobile Phone Users 2Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 2Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 3Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 4Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 5Health News:SCAI and ACC announce new interventional cardiology meeting 2Health News:Medicare Spending Caps Cause Seniors to Stop Meds 2Health News:ASTRO, Wellness Community South Bay Cities Join to Promote Cancer Survivorship 2Health News:Weight Gain May Spell Trouble for Heart Failure Patients 2
... providers can code the charge while completing a ... while away from office, both directly feeding the ... an Encounter Form/Superbill, data entry can be done ... patient payments are posted by reflecting open item ...
The CH 2000 Cardiac Diagnostic system is a fully featured stress testing system that can include Microvolt T-Wave Alternans (MTWA) testing capability as an add-on feature. , ,Interfaces with Tra...
The HearTwave system is the original stand-alone Microvolt T-Wave Alternans (MTWA) testing platform....
... features 4 precisely angled 64° mirrors to ... anterior chamber angle with slight rotation. ... element) provides a stable platform during laser ... mirror lens provides a complete view of ...
Medicine Products: